Pervasis Therapeutics, Inc.

One Kendall Square, Ste. B6101

Cambridge, MA  02139

Tel: 617.621.3407


Leadership:
Frederic Chereau
President & CEO


Website:
www.pervasistx.com

Pervasis Therapeutics, Inc.

Initial Investment: 
2003
Status: 
Private

Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs. The Company’s most advanced program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 trials in patients undergoing vascular access for hemodialysis. In addition, Pervasis is pursuing a cell-based oncology program focused on targeting and regulating cell stroma in order to prevent key processes that play a role in advancing solid tumor growth and survival. Pervasis is also applying its platform technology to develop products in other key therapeutic areas including inflammatory disease and orthopedic injury.

Ed Kania is on the Board of Directors.